FDA (CDER)
GUIDANCE DRAFT
Development of Non-Opioid Analgesics for Acute Pain
Published: 5/13/2026Detected: 5/13/2026
Summary preview
Development of Non-Opioid Analgesics for Acute Pain draft guidance is intended to shape how sponsors design and justify non-opioid acute pain programs, with particular emphasis on the clinical evidence needed to support…
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountneurology
pediatrics
#acute pain
#non-opioid analgesics
#clinical trials
#efficacy endpoints
#adverse events
Official Source Document Source Verified
Access the original document directly from FDA CDER.
More from FDA (CDER)
- E14 and S7B Clinical and Nonclinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential--Questions and Answers (R1): Guidance for Industry10/30/2026
- Submitting Clinical Trial Data to Evaluate the Ability to Operate a Motor Vehicle10/20/2026
- Regulatory Considerations for Prescription Drug Use-Related Software10/20/2026
- Safety Reporting Requirements for INDs and BA/BE Studies: Guidance for Industry and Investigators10/19/2026
- Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products: Questions and Answers10/9/2026